Open AccessHepatectomy Followed by Adjuvant Chemotherapy with 3‐Month Capecitabine Plus Oxaliplatin for Colorectal Cancer Liver Metastases
Author(s) -
Satake Hironaga,
Hashida Hiroki,
Tanioka Hiroaki,
Miyake Yasuhiro,
Yoshioka Shinichi,
Watanabe Takanori,
Matsuura Masato,
Kyogoku Takahisa,
Inukai Michio,
Kotake Takeshi,
Okita Yoshihiro,
Matsumoto Toshihiko,
Yasui Hisateru,
Kotaka Masahito,
Kato Takeshi,
Kaihara Satoshi,
Tsuji Akihito
Publication year - 2021
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1002/onco.13816
Subject(s) - capecitabine , medicine , oxaliplatin , clinical endpoint , colorectal cancer , neutropenia , adjuvant , oncology , chemotherapy , surgery , gastroenterology , cancer , randomized controlled trial
Lessons Learned Three‐month adjuvant capecitabine plus oxaliplatin in combination (CAPOX) appeared to reduce recurrence, with mild toxicity in postcurative resection of colorectal cancer liver metastases (CLM). Recurrence in patients who underwent the 3‐month adjuvant CAPOX after resection of CLM was most commonly at extrahepatic sites.Background The role of neoadjuvant and adjuvant chemotherapy in the management of initially resectable colorectal cancer liver metastases (CLM) is still unclear. We evaluated the feasibility of 3‐month adjuvant treatment with capecitabine plus oxaliplatin in combination (CAPOX) for postcurative resection of CLM. Methods Patients received one cycle of capecitabine followed by four cycles of CAPOX as adjuvant chemotherapy after curative resection of CLM. Oral capecitabine was given as 1,000 mg/m 2 twice daily for 2 weeks in a 3‐week cycle, and CAPOX consisted of oral capecitabine plus oxaliplatin 130 mg/m 2 on day 1 in a 3‐week cycle. Primary endpoint was the completion rate of adjuvant chemotherapy. Secondary endpoints included recurrence‐free survival (RFS), overall survival (OS), dose intensity, and safety. Results Twenty‐eight patients were enrolled. Median age was 69.5 years, 54% of patients had synchronous metastases, and 29% were bilobar. Mean number of lesions resected was two, and mean size of the largest lesion was 31 mm. Among patients, 20 (71.4%; 95% confidence interval, 53.6%–89.3%) completed the protocol treatment and met its primary endpoint. The most common grade 3 or higher toxicity was neutropenia (29%). Five‐year recurrence‐free survival and overall survival were 65.2% and 87.2%, respectively. Conclusion Three‐month adjuvant treatment with CAPOX is tolerable and might be a promising strategy for postcurative resection of CLM.